NCT07012538View on ClinicalTrials.gov

RASi for Preventing Postoperative Recurrence of Stage II/III Colon Cancer

CompletedOBSERVATIONAL
Enrollment

2,640

Participants

Timeline

Start Date

January 4, 2012

Primary Completion Date

December 30, 2021

Study Completion Date

April 30, 2025

Conditions
Colon Cancer (Stage II &Amp;Amp; III)
Interventions
DRUG

Renin-angiotensin system inhibitors (RASi)

Using RASi after radical resection of stage II/III colon cancer for at least 3 years or till recurrence or death or inappropriate use of RASi.

DRUG

No renin-angiotensin system inhibitors (No RASi)

Not using RASi after radical resection of stage II/III colon cancer for at least 3 years or till recurrence or death or needing RASi.

Trial Locations (1)

200032

Zhongshan Hospital Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT07012538 - RASi for Preventing Postoperative Recurrence of Stage II/III Colon Cancer | Biotech Hunter | Biotech Hunter